Home › Funds › Bain Capital Life Sciences Investors, LLC › NAMS

Bain Capital Life Sciences Investors, LLC position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

Bain Capital Life Sciences Investors, LLC reported holding 3,806,559 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$92.6M, representing 6.37% of its reported portfolio and ranking #5 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)3.81M sh
Reported value held$92.58M
Portfolio Weight6.37%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Bain Capital Life Sciences Investors, LLC's NAMS position evolved

Bain Capital Life Sciences Investors, LLC first disclosed a stake in NAMS in Q3 2023 at 10,473,913 shares (US$96.9M). The position peaked in Q3 2025 at 10,719,110 shares, worth US$304.9M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 3,806,559 shares valued at US$92.6M. Notable position changes include a 32% trim in Q4 2025 (shares fell 9% over the following quarter), a 48% trim in Q2 2026 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 10.47M $96.88M New
Q4 2023 10.47M $116.99M Hold
Q1 2024 10.47M $247.71M Hold
Q2 2024 10.47M $201.20M Hold
Q3 2024 10.47M $173.87M Hold
Q4 2024 10.72M $275.48M Add
Q1 2025 10.72M $219.42M Hold
Q2 2025 10.72M $194.12M Hold
Q3 2025 10.72M $304.85M Hold
Q4 2025 7.31M $256.31M Reduce
Q1 2026 7.31M $233.88M Hold
Q2 2026 3.81M $129.00M Reduce
Q3 2026 3.81M $92.58M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 39 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$206.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has Bain Capital Life Sciences Investors, LLC held NAMS?

Bain Capital Life Sciences Investors, LLC has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Bain Capital Life Sciences Investors, LLC's current position in NAMS?

As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 3.81M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $92.58M, representing 6.37% of its reported portfolio and ranking #5.

Has Bain Capital Life Sciences Investors, LLC been buying or selling NAMS?

In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in NAMS. The position peaked in Q3 2025 at 10.72M shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.